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0022-2836 © 2012 Elsevier Ltd. Open accThe formation of the CBM (CARD11–BCL10–MALT1) complex is pivotal
for antigen-receptor-mediated activation of the transcription factor NF-κB.
Signaling is dependent on MALT1 (mucosa-associated lymphoid tissue
lymphoma translocation protein 1), which not only acts as a scaffolding
protein but also possesses proteolytic activity mediated by its caspase-like
domain. It remained unclear how the CBM activates MALT1. Here, we
provide biochemical and structural evidence that MALT1 activation is
dependent on its dimerization and show that mutations at the dimer
interface abrogate activity in cells. The unliganded protease presents itself in
a dimeric yet inactive state and undergoes substantial conformational
changes upon substrate binding. These structural changes also affect the
conformation of the C-terminal Ig-like domain, a domain that is required for
MALT1 activity. Binding to the active site is coupled to a relative movement
of caspase and Ig-like domains. MALT1 binding partners thus may have the
potential of tuning MALT1 protease activity without binding directly to the
caspase domain.© 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction
Lymphocytes play an important role in the
adaptive immune response. Their activation is
triggered by binding of speciﬁc antigens to surface
receptors, which initiates downstream signaling.ress:
chemical Institute of
strasse 190, CH-8057
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ess under CC BY-NC-ND licenMost prominent are the NF-κB pathways that
ultimately lead to the activation of the IKK (IκB-
kinase) complex and to the nuclear translocation of
the transcription factor NF-κB. Recent studies on
antigen-receptor-regulated IKK activation revealed
the so-called CBM (CARD11–BCL10–MALT1) com-
plex as an important node in this pathway. The CBM
consists of the three molecules, CARD11, BCL10 (B-
cell CLL/lymphoma 10), and MALT1 (mucosa-
associated lymphoid tissue lymphoma translocation
protein 1). The exact stoichiometry of the complex,
as well as the contribution of each component to
CBM function, is largely unknown. CARD11, a 130-
kDa multi-domain protein also known as CARMA1,
seems to function as scaffolding protein. It is
believed to interact with BCL10, a 26-kDa-protein
adaptor protein, through a CARD–CARD interac-
tion and potentially with MALT1 through the
coiled-coil domain,1 which may contribute to CBM
complex stabilization and MALT1 activation.se.
5Determinants of MALT1 Protease ActivityEndogenous BCL10 is constitutively in complex
with MALT1, a 92-kDa multi-domain protein.
MALT1 was ﬁrst identiﬁed in the chromosomal
translocation t(11;18)(q21;q21)2,3 where the cIAP-2
(cellular inhibitor of apoptosis protein-2) gene is
fused to the MALT1 locus. The resulting cIAP2-
MALT1, or BIRC3-MALT1, fusion protein acts as a
constitutive activator of the NF-κB pathway. Al-
though MALT1 contains a putative protease do-
main, protease activity in vitro or in cells could not
be demonstrated unambiguously4,5 for a long time.
MALT1 appeared to be a cryptic protease that had
lost its protease activity during evolution and
mediates CBM activation through scaffolding.
However, 4 years ago, two independent studies
showed that MALT1 indeed possesses proteolytic
activity and that this activity is crucial for its
function through the processing of BCL10 and
A20, the ﬁrst physiological MALT1 substrates
described.6,7
MALT1 has been recognized as a distant relative
of caspases, in an attempt to identify their evolu-
tionary origin.5 Caspases are best known as cell
death proteases (e.g., caspase-3, caspase-7, caspase-
8, and caspase-9) but are also key players in
inﬂammation (e.g., caspase-1). Pro-apoptotic cas-
pases function in cascades where an upstream or
initiator caspase (e.g., caspase-8 and caspase-9)
activates downstream caspases (e.g., caspase-3 and
caspase-7), which cleave a variety of substrates and
are responsible for the execution of the cell death
program. Initiator and executioner caspases, as well
as the pro-inﬂammatory caspases, are only active as
dimers. However, while executioner caspases are
obligate dimers and activated via limited proteolysis
of the so-called inter-domain linker, initiator cas-
pases remain in an inactive, monomeric form until
they are activated by dimerization, triggering the
processing of their inter-domain linker. Activation
in cells is driven by induced proximity through the
formation of supramolecular activation platforms
such as the PIDDosome (activation of caspase-28),
the apoptosome (activation of caspase-99), or the
DISC (activation of caspase-89).
Based on the analogy to caspases, it is likely that
MALT1 exists as an inactive monomer and is
activated by oligomerization/dimerization in the
CBM. To study how the proteolytic activity is
triggered and regulated, we produced proteolyti-
cally active MALT1, and we investigated the
structural determinants of MALT1 activity. Indeed,
protease activity requires MALT1 dimerization,
which can be induced in vitro by binding of a
peptidic irreversible inhibitor. The structure of
MALT1 in a ligand-free state and modiﬁed with a
covalently bound peptidic inhibitor explains the
strict speciﬁcity of MALT1 for arginine in P1 and
allows rationalization of how MALT1 is activated in
the absence of limited proteolysis.While this manuscript was in preparation, another
group published the structure of human MALT1
in complex with the covalent inhibitor Z-VRPR-
ﬂuoromethylketone (fmk).10
Results and Discussion
Proteolytic activity of MALT1 depends on
dimerization
Human MALT1 is an 824-amino-acid-long multi-
domain protein (Fig. 1a). A death domain (DD) and
two immunoglobulin-like domains (Ig1 and Ig2) of
known three-dimensional structure11 precede a
caspase-like domain,5 a third Ig-like12 domain
(Ig3), and 100 C-terminal residues with no recogniz-
able domain signature. However, it almost took a
decade to show unambiguously that MALT1 is not
only a scaffolding protein but also a functional
protease.6,7 The published data suggest that MALT1
is in a resting state, unless activated by induced
proximity. For example, in vitro processing of a
peptide substrate, which is based on the recognition
site LRSR of the endogenous substrate BCL10, is
dependent on matrix-induced proximity (glutathi-
one S-transferase-MALT1 fusion protein bound to
glutathione S-transferase beads7). In another study
in vitro, cleavage of the endogenous MALT1
substrate A20 relies on oligomerization induced by
fusion partners (MALT1-gyrase B fusion protein)
and the presence of kosmotropic salts in the assay
buffer. 6 Prompted by these observations, we
addressed two fundamental questions: which
MALT1 domains are required to sustain protease
activity and what drives MALT1 activity?
After setting up an expression system for human
full-length MALT1DD-Ig1-Ig2-Casp-Ig3-Cterm (2–824) in
insect cells, we generated domain deletion mutants
to reduce the complexity of the protease (Supple-
mentary Figs. 1–3). Deletion of the three N-terminal
domains yielded a well-expressed protein referred
to as hMALT1Casp-Ig3-Cterm (329–824) and, as already
observed for full-length MALT1, is largely mono-
meric during puriﬁcation. In contrast, deletion of the
domains C-terminal to the caspase domain are not
tolerated: hMALT1DD-Ig1-Ig2-Casp (2–566) and the
isolated caspase domain hMALT1Casp (329–566)
yielded only oligomeric, poorly folded protein.
Therefore, subsequent functional and structural
studies focused on variants that comprised the
catalytic domain and additional C-terminal do-
main(s). Samples dedicated for enzymatic studies
were expressed using insect cells, as most of the
multi-domain variants of MALT1 could not be
expressed efﬁciently in Escherichia coli. However,
the truncation variant hMALT1Casp-Ig3 (334–719)
could be expressed in E. coli and was used to solve
the hMALT1Casp-Ig3 apostructure (see below).
Fig. 1. Enzymatic characterization ofMALT1. (a) Domain structure of humanMALT1. The nomenclature for describing
different variants used throughout this study is based on this ﬁgure. For example, MALT1DD-Ig1-Ig2-Casp-Ig3-Cterm stands
for full-length MALT1 (1–824). (b) In vitro MALT1 is only active in the presence of kosmotropes, and residues 1–328 are
not required for activity in vitro. Turnover of the substrate Ac-LRSR-Rh110-DP by human MALT1 (2–824) and the N-
terminally truncated variant MALT1Casp-Ig3-Cterm (329–824), both expressed from insect cells, was determined in 200 mM
Tris–HCl (pH 7.5), 0.1 mM EGTA, 0.05% Chaps, and 1 mM DTT in the presence of increasing concentrations of sodium
citrate. Substrate turnover was monitored for 80 min , and the increase in ﬂuorescence intensity at 40 min is shown.
Each value is the average of duplicates. (c) MALT1 activity in a CBM reconstitution assay is dependent on the integrity
of the third Ig-like domain. CARD11 (activation mutant L244P13), full-length BCL10, and MALT1 variants were
transfected into HEK293 cells. MALT1 protease-dependent BCL10 cleavage (see also Ref. 7) was monitored with a neo-
epitope antibody that recognizes the new C-terminus of BCL10, which is generated by the MALT1 speciﬁc cleavage at
Arg228. (“Cleaved BCL10”). Total amounts of BCL10 (cleaved and uncleaved) expressed were monitored with an
antibody recognizing the coiled-coil region 168–233. Appearance of a signal for “Cleaved BCL10” indicates that the
MALT1 variant is active. All three components of the CBM are required for MALT1 activity and BCL10 cleavage (left
panel). Steady-state levels of the variant MALT1 (1–706) were reproducibly lower than full-length human MALT1 levels
and correlated with reduced levels of co-expressed BCL10.
6 Determinants of MALT1 Protease ActivityMALT1 cleaves peptide substrates such as the
BCL10-based substrate7 Ac-LRSR-Rh110-DP only
when kosmotropes such as sodium citrate are
added to the assay buffer (Table 1, Fig. 1b, and
Supplementary Figs. 3 and 4). This processing is
dependent on the catalytic activity of the MALT1
caspase-like domain, as the active-site mutant
MALT1 (2–824) C464A is no longer able to cleave
the substrate, even in the presence of kosmotropes
(Supplementary Fig. 3b). Consistent with the do-
main mapping experiments, deletion of the N-terminal domains of MALT1 had little inﬂuence on
the protease activity under these conditions (Fig. 1b
and Supplementary Fig. 3). Next, different MALT1
variants were incubated with the peptide-based
inhibitor Z-VRPR-fmk.7 Again, while MALT1Casp
(329–569) does not react with the inhibitor, covalent
adducts are observed with hMALT1Casp-Ig3-Cterm or
hMALT1Casp-Ig3 (data not shown). Most important-
ly, covalent irreversible modiﬁcation of the active-
site cysteine induces the formation of a stable,
dimeric species that can be separated from
Table 1. Steady-state kinetic parameters for MALT1
substrates
Substrate
kcat
(s−1) Km (M)
kcat/Km
(s−1 M−1)
Ac-LISR-amca 141.1 1.0×10−4 1.4×106
Ac-LRSR-Rh110-DP
b 28.9 7.5×10−5 3.9×105
a Measured in 25 mM Hepes–NaOH (pH 7.4), 0.1 mM EDTA,
0.05% Chaps, 1 mM TCEP, and 0.8 M sodium citrate using 290-
nM ZZ-tagged full-length human MALT1 (2–824) and 0- to 600-
μM substrate.
b Measured in 200 mM Tris–HCl (pH 7.5), 0.1 mM EGTA,
0.05% Chaps, 1 mM DTT, and 0.8 M sodium citrate using 75-nM
ZZ-tagged full-length human MALT1 (2–824) and 2.5-, 3.125-, 5-,
6.25-, 10-, 12.5-, 20-, 25-, 40-, 50-, 80-, and 100- μM substrates.
7Determinants of MALT1 Protease Activityunmodiﬁed, monomeric MALT1 by size-exclusion
chromatography (Supplementary Fig. 5).
As kosmotrope-induced activation in vitro is
highly artiﬁcial, the signiﬁcance of the C-terminus
of MALT1 for protease activity under physiological
conditions was explored. To this end, we used a
CBM assay in HEK293 cells (Fig. 1c). The assay is
based on the reconstitution of the CBM complex by
overexpression of the three components CARD11,
BCL10, and MALT1. The CARD11 protein carries
the activation mutation L244P.13 MALT1 protease
activity is monitored by quantiﬁcation of cleaved
BCL10 using a neo-epitope antibody speciﬁc for the
MALT1-dependent cleavage product, as described
by others.7 Because the N-terminal domains are
required for the interaction with BCL10,14 only C-
terminally truncated variants but no N-terminally
truncated variants were tested. Full-length MALT1
(1–824) and the C-terminal truncation variants 1–
781, 1–726, and 1–717 cleave BCL10 with similar
efﬁciency as indicated by the similar relative
intensities of cleaved versus total BCL10 (Fig. 1c).
However, truncations into the predicted Ig3-like
domain as inMALT1 (1–706) eliminate processing of
BCL10, probably by destabilization of MALT1, an
interpretation that was subsequently supported by
the structure of MALT1Casp-Ig3 (see below). Al-
though the assay does not allow to distinguish the
relative activity of the three truncation mutants
MALT1 (1–781), MALT1 (1–726), and MALT1 (1–
717), we concluded from the domain mapping and
the CBM reconstitution assay that caspase and Ig3
domains, but not the C-terminus (718–834), are
required to support MALT1 integrity and protease
activity.
In summary, these data show that MALT1 activity
in vitro can be induced by dimerization and reveal a
strong similarity in the activation mechanism of
MALT1 and initiator caspases. The initiator caspase-
2, caspase-8, and caspase-9 are inactive as mono-
mers with dimerization representing the crucial step
in their activation.15,16 Heterologously expressed
initiator caspases exist as a mixture of monomersand dimers. Although the relative distribution of
monomers and dimers differs between these cas-
pases, protease activity is conﬁned to the fractions
containing dimeric protein. Kosmotropic salts that
stabilize hydrophobic interactions and hence facili-
tate caspase dimerization strongly enhance the in
vitro activity of initiator caspases.17–21 However, all
caspases are processed in the inter-domain linker,
leading to the formation of the caspase typical two-
chain molecule consisting of a large subunit and a
small subunit. In the activation of executioner
caspases (such as caspase-3, caspase-6, and cas-
pase-7), limited proteolysis is the key step, whereas
processing of initiator caspases is not required for
activation but serves additional functions, such as
stabilization of the active dimer (caspase-2 and
caspase-817,22) or rendering the enzyme susceptible
to inhibition (caspase-923). In contrast, MALT1 is not
processed within the boundaries of the caspase
domain.
The overall structure of hMALT1
Based on the domain mapping experiments (Fig. 1
and Supplementary Fig. 3), variants comprising the
caspase and the third Ig-like domain were selected
for structural studies. The construct humanMALT1-
Casp-Ig3 (334–719) expressed well in E. coli. binds the
covalent inhibitor Z-VRPR-fmk, and in the CBM
reconstitution assay (Fig. 1c), a corresponding
construct ending at 717 is active. A mixture of
monomeric and dimeric species could be separated
by standard chromatographic methods. The dimeric
form yielded crystals of hMALT1Casp-Ig3 that dif-
fract to 1.8 Å resolution. The asymmetric unit
contains one molecule of hMALT1Casp-Ig3 with the
biologically relevant dimer being generated by a
crystallographic 2-fold axis (Fig. 2a; for a stereo
ﬁgure, see Supplementary Fig. 6). As predicted, the
228-amino-acid-long catalytic domain of hMALT1
(345–566) adopts the general caspase fold (Fig.
2b). 24,25 Brieﬂy, the caspase domain of each
MALT1 monomer contains a six-stranded β-sheet
(β2, β1, β3, β4, β7, and β8) in its center that is
ﬂanked on one side by the three helices αA, αD, αE
and on the other side by the two helices αB and αC
(Fig. 2a). The dimer interface between the two
MALT1 monomers is formed by interactions be-
tween β8 and αF with their respective symmetry
mates β8′ and αF′. As in caspases, this leads to the
formation of a contiguous 12-stranded β-sheet in the
center of the protein with the active sites positioned
on opposite faces of the central β-sheet and
separated by approximately 40 Å (Fig. 2). C-termi-
nal to the caspase domain, MALT1 has a short
extended linker that is only poorly deﬁned in the
electron density and connects to helix α1Ig3. This
helix packs closely against helix αC and the
outermost strand β2 of the caspase domain and, in
Fig. 2. The structures of ligand-free human MALT1Casp-Ig3 (334–719) (a–c) and murine MALT1Casp-Ig3 (338–728) in
covalent complex with the peptidic inhibitor Z-VRPR-fmk. (d) Secondary structure elements on the caspase domain are
numbered as published for caspase-1.25 (a) The biologically relevant dimer of ligand-free hMALT1Casp-Ig3 is generated by
a crystallographic 2-fold axis. One monomer is colored rainbow; the other, light blue. The active-site residues C464 and
H415 are shown as sticks. The substrate binding loops L2, L3, and L4 are highlighted in red. Loop L2 between 467 and 580
and the linker between caspases and Ig3 domain (567–569) are not deﬁned by electron density and indicated by a dotted
line. (b) Superimposition of the caspase domains of hMALT1 (blue) and caspase-9 (PDB code 1jxq; inactive monomer in
yellow). (c) Superimposition of the Ig3 domain (blue) with the α-ear domain of the AP-2 adaptor (PDB entry 1ky6) in
yellow. hMALT1 residues 634–667 differ substantially from the AP-2 structure and are shown in red. Residue E653, which
mediates the interaction with TRAF6, is highlighted by sticks. Strand βD of the AP-2 structure, which is absent inMALT1,
is labeled as Dear. (d) As for ligand-free hMALT1Casp-Ig3, the biologically relevant dimer of mMALT1Casp-Ig3/Z-VRPR-fmk
is generated by a crystallographic 2-fold axis. One monomer is colored rainbow; the other, lime. The peptidic inhibitor is
shown as orange sticks.
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Fig. 3. MALT1 is homologous to caspases: sequence alignment of MALT1 catalytic domain with the catalytic domains
of human caspase-1, caspase-2, caspase-3, and caspase-9 (PDB entries 1ice, 1pyo, 1pau, and 1jxq). Secondary structure
elements are numbered as published for caspase-1.25 The loops L1, L2, L3, and L4 ﬂanking the substrate binding site are
numbered as published for caspase-7.19 Numbers refer to the amino acid position in MALT1 (top row) and to the one in
caspase-1 (bottom row). Residues in the inter-domain linker of caspase-1, caspase- 2, caspase-3, and caspase-9 that are not
present in the structures are called in small letters; cleavage sites in that region are boxed. Conserved active-site cysteine
and histidine residues are highlighted by a red star, and residues deﬁning the S1 speciﬁcity andMALT1 residues involved
in the stabilization of the active conformation are colored according to the charge of the side chain.
9Determinants of MALT1 Protease Activityturn, connects to a seven-stranded sandwich span-
ning residues 584–719 (Fig. 2a and c). This domain
has been predicted correctly to be an Ig-like
domain;12 however, it differs substantially from the
canonical Ig-like architecture. Ig-like domains gen-
erally consist of two β-sheets, one of which is formed
by strands βA, βB, βE, and βD, while the other
contains strands βC, βF, and βG. In MALT1, the
“ABED” sheet is complemented by an additional
strand βA0 that is preceding strand βA. In addition,
the domain lacks strand βD and has a very short
strand βE. The topology of the ABED sheet in
MALT1Ig3 therefore is “A
0ABE”. While the lack of
strand D is so far unique toMALT1Ig3, the additional
strand A0 is also present in the so-called “ear
domains”, domains that are known mediators for
protein–protein interactions. The closest structural
homologue of MALT1 is the ear domain of the
adaptor protein “AP-2”, where it plays a crucial role
in clathrin-mediated endocytosis by mediating the
interaction with accessory proteins.26–28 Although
the primary sequences are unrelated, MALT1Ig3
(585–716) superimposes onto the ear domain of
AP-2 [Protein Data Bank (PDB) code 1ky6] with an
rmsd of 1.7 Å over 86 common Cα positions (Fig. 2c).
Comparison of MALT1Ig3 to ear domains and otherIg-like domains shows that residues 655–676 should
form strands D and E and the loop connecting the
two strands. However, in MALT1Ig3, these residues
are folded back on top of the domain, adopting an
irregular structure with four short helix segments
that form a lid-like structure. This lid is in contact
with residues from strands βA, βB, and βE of the Ig-
like domain and forms hydrophobic interactions
with residues from the L1 and L3 loops of the caspase
domain (Figs. 2 and 3). E653, which together with
E806 has been described as one of two mediators
between MALT1 and human TRAF6,29 is located on
a helical segment of the lid and is solvent exposed
(Fig. 2c). TRAF6 plays an important role in theNF-κB
pathway downstream of MALT1. Binding of TRAF6
to MALT1 activates its ubiquitin ligase activity by
triggering self-oligomerization.29,30 In its current
position on a short helical turn, E653 is most likely
unable to interact efﬁcientlywith a large protein such
as TRAF6. However, an assumed structural rea-
rrangement from its present position to a conforma-
tion analogous to the AP-2 ear domainwould lead to
the formation of the missing strand βD. In this
conformation, E653 would be located at the tip of
MALT1Ig3 domain and accessible for interactionwith
TRAF6.
10 Determinants of MALT1 Protease ActivityLigand-free MALT1Casp-Ig3 is in an inactive state
According to a database search†, the closest
structural relative of the unliganded MALT1 cas-
pase domain is caspase-923,31 (PDB codes 1jxq and
1nw9). However, only about 30 amino acids of the
229 residues of caspase domains are conserved
between the primary sequences of the two proteins
(Fig. 3). Caspase-9 forms an asymmetrical dimer in
which one active site is in a catalytically competent
conformation and the second active site adopts an
inactive conformation.31 Superposition of hMALT1-
Casp-Ig3 onto the inactive form of caspase-9 yields an
rmsd of less than 2.0 Å for 183 common Cα
positions, which is slightly better than the one for
the superimposition onto the active form. As
expected, the secondary structure elements are
highly conserved between the two structures, and
most of the changes occur in ﬂexible loops connect-
ing them (Fig. 2a, b, and d). Closer inspection of
MALT1 and comparison with caspases reveal that
the enzyme, albeit in its dimeric form and without
the requirement of further processing to be active,
has crystallized in an inactive state: loop L2
(residues 463–485), which carries the active-site
cysteine C464 and forms the linker between the
large and small subunits in caspases, appears
ﬂexible in MALT1 with residues 467–480 completely
disordered in the electron density. The segments of
L2 that remain deﬁned in the structure adopt a
conformation similar to the one observed in pro-
caspase-1 and pro-caspase-7 and the inactive form of
caspase-9.23,31 In this “inactive form”, the Sγ of the
active-site cysteine, C464 in MALT1, is not in its
catalytically competent position and unable to form
the proper catalytic dyad with H415. Furthermore,
the S1 pocket ofMALT1 is occupied by the side chain
of Q494 preventing access of potential substrates.
Q494 is located on the L3 loop, a loop that carries
many residues that are crucial for substrate recog-
nition (Fig. 4) and forms the base of the catalytic
groove in active caspases. In MALT1Casp-Ig3, this
loop isﬂexible as indicated by increased temperature
factors but could be unambiguously placed in the
electron density with exception of residues 495, 496,
and 497. It adopts a conformation present in the
other inactive procaspases. In summary, the ligand-
free hMALT1Casp-Ig3 presents itself as an inactive
protease with a dislocated nucleophile, a disabled
substrate recognition site, and an occupied, auto-
inhibited S1 pocket (Fig. 4a and b).
The key step in the maturation of executioner
caspase as exempliﬁed for caspase-719 is the
formation of a loop bundle between L2, L4, and
L2′ (L2 contributed by the second caspase domain in
the dimer), which ultimately leads to the formation†http://www.ebi.ac.uk/msd-srv/ssm/of an active Cys–His dyad and a functional substrate
recognition groove. Formation of this bundle is
dependent on proteolytic processing of the inter-
domain linker L2, whereas MALT1 protease activa-
tion is independent of limited proteolysis. This
raises the question as to how the active conforma-
tion is stabilized in MALT1. To this end, we
crystallized MALT1 in complex with a substrate-
like inhibitor.
MALT1 in complex with a peptidic inhibitor is in
an active conformation
Reactive peptide-like inhibitors have been used
in the past not only to explore the speciﬁcity of
caspases and their inhibition but also to further
understand their activation mechanism on a
structural level. In our studies, monomeric human
or murine MALT1Casp-Ig3-Cterm were treated with
the reactive peptidic inhibitor Z-VRPR-fmk7 to
generate irreversibly modiﬁed dimers (for a repre-
sentative example, see Supplementary Fig. 5).
While murine MALT1Casp-Ig3/Z-VRPR-fmk (resi-
dues 338–729 in the murine sequence) yielded
crystals that diffracted to 3.15 Å, well-diffracting
crystals of human MALT1Casp/Z-VRPR-fmk were
only obtained after limited proteolysis of inhibited,
dimeric hMALT1Casp-Ig3-Cterm (329–824) with chy-
motrypsin. The resulting covalently modiﬁed
MALT1Casp contains residues 329–566 and presents
a stable, dimeric entity that crystallized rapidly and
diffracts to 2.1 Å (Table 2).
Crystals of hMALT1Casp/Z-VRPR-fmk and
mMALT1Casp-Ig3/Z-VRPR-fmk contain a single
covalently modiﬁed molecule of MALT1 in the
asymmetric unit, with crystallographic symmetry
completing the biologically relevant dimer. As
expected from the high degree of identity, human
and murine MALT1 sequences differ in only six
positions within the caspase domain, both struc-
tures are virtually identical and superimpose with
an rmsd of 0.3 Å (226 equivalent Cα positions).
The only differences occur in a stretch of seven
amino acids in loop L4, most likely the result of
different crystal packing environments. For the
description of ligand binding (Fig. 4), the structure
of hMALT1Casp/Z-VRPR-fmk was used, as this is a
higher-resolution structure.
Binding of the covalent peptidic inhibitor induces
the active conformation of MALT1. This transition
involves structural changes especially in the loops
L2, L3, and, to a lesser extent, L4, which delineate
the active site but propagate throughout the
molecule (Fig. 2a and d). Most prominently, loop
L2, which is disordered in the inactive state of
ligand-free MALT1, can be fully traced in the
electron density of the inhibitor-bound structures.
The active-site cysteine C464 is in an active
conformation when compared to other active
11Determinants of MALT1 Protease Activitycaspases such as caspase-2.32 Residues on L3 move
up to 16 Å upon covalent modiﬁcation with the
inhibitor. Instead of running directly “west” (refer-
ring to the standard orientation used in Fig. 4),
residues 491–498 now form a short elbow loop (Figs.
3 and 4b). Consequently, the amide group of Q494,Fig. 4 (legend on next page)which occupies the S1 pocket of the inactive
apoenzyme, moves 18 Å toward the dimer interface.
This elbow contributes substantially to stabilization
of the active conformation, as it is engaged in a
network of hydrogen bond and charge–charge
interactions with L2 (Fig. 4b). Although residues in
Table 2. Diffraction and reﬁnement statistics
hMALT1Casp-Ig3 hMALT1Casp mMALT1Casp-Ig3
Ligand Ligand free With Z-VRPR-fmk With Z-VRPR-fmk
Expression system E. coli BL21 DE3 S. frugiperda SF 21 S. frugiperda SF 21
Boundaries 334–719 329–569 338–728
Data collectiona
Space group C2 P6122 P6222
Cell dimensions
a, b, c (Å) 96.7, 67.3, 58.0 77.5, 77.5, 180.5 150.9, 150.9, 91.8
α, β, γ (°) 90, 97.3, 90 90, 90, 120 90, 90, 120
Resolutionb (Å) 41.33–1.807 (1.813–1.807) 67.11–2.10 (2.15–2.10) 60.00–3.15 (3.28–3.15)
Rsym
b (%) 4.3 (45.8) 9.5 (53.6) 14.9 (80.3)
I/σ(I)b 15.4 (2.3) 13.2 (3.6) 18.3 (3.8)
Completenessb (%) 97.7 (97.6) 99.7 (99.7) 98.5 (97.5)
Redundancyb 3.3 (3.2) 5.2 (5.3) 13.5 (13)
Reﬁnement
Resolutionb (Å) 41.33–1.81 (1.87–1.81) 53.86–2.1 (2.1–2.16) 60.00–3.15 (3.45–3.15)
No. of reﬂections 32,785 18,482 10,950
Rcryst
b/Rfree
b (5% of data) 19.63 (23.7)/24.8 (29.4) 17.9 (20.6)/22.8 (25.6) 17.37 (21.6)/23.0 (30.4)
Final model
Non-hydrogen atoms 3011 2064 3111
Ligand 0 47 47
Water molecules 255 150 0
Bond length rmsd (Å) 0.01 0.014 0.011
Bond angles rmsd (°) 1.2 1.56 2.9
a For all three structures, one crystal was used for data collection.
b The values in parentheses correspond to the highest-resolution shell.
12 Determinants of MALT1 Protease Activitythe elbow loop show only moderate conservation
among the caspases, the elbow is formed in all
structures of caspases in their active state reported
today but is not present in pro-caspase structures or
the inactive forms of caspase-9. In MALT1, the
elbow partially shields the guanidinium group of
R465, which is sandwiched between the carboxyl-
ates of E418 and E549 and stacking on top of Y490
(see also Fig. 6c and d). These interactions lock the
position of R465, bring the preceding active-site
C464 in its active conformation, and place L3 in a
position to align substrates for proteolysis.
The ligand binds in an extended conformation
In the MALT1/Z-VRPR-fmk complexes, the nu-
cleophile of the catalytic site cysteine (Sγ of C464) is
irreversibly alkylated by the peptidic inhibitor withFig. 4. The active site of MALT1. Ligand-free humanMALT1
569) in complex with the peptidic inhibitor Z-VRPR-fmk (ora
inhibitor acetyl-LDESD-aldehyde is colored yellow. Residues in
sticks. (a) hMALT1Casp-Ig3 in its ligand-free form. The side c
induces structural changes. The peptidic inhibitor has been om
some residues that change their position during this transitio
(green). (d) The ﬁnal 2Fo−Fc density contoured at 1 σ for the
Superimposition of hMALT1Casp/Z-VRPR-fmk (green, orang
code 1pyo; yellow). Caspase-2 residues are labeled in italics usi
caspase-2 residues that are in direct interaction with the P1 resi
Superimposition of Z-VRPR-fmk (MALT1, orange) and acetylthe Nδ1 atom of H415, the second residue of the
catalytic dyad, in hydrogen bonding distance to the
methyl ketone oxygen of the inhibitor. The side
chains of H415 and C464 are 6 Å apart and
separated by the substrate binding cleft. This
suggests that the histidine contributes to catalysis
by stabilizing the negative charge of the tetrahedral
intermediate rather than increasing the nucleophi-
licity of C464 (Fig. 4). The P1 arginine of the inhibitor
occupies the S1 pocket and directly interacts with
the carboxylates of D365 and E500. Its positive
charge is further balanced by D462, a third
potentially negatively charged residue lining the
S1 pocket (Fig. 4c, d and e). These interactions offer
an explanation why lysine is not accepted as P1
residue (Fig. 5c): the Nɛ of a lysine in the position of
arginine Cζ would not be able to engage in any of
these interactions. The “south” of the S1 pocketCasp-Ig3 (334–719) is colored blue, humanMALT1Casp (329–
nge) is colored green, and caspase-2 in complex with the
volved in substrate recognition and catalysis are shown as
hain of Q494 occupies the S1 pocket. (b) Ligand binding
itted for clarity. To illustrate structural changes, we labeled
n. (c and d) Interaction of Z-VRPR (orange) with MALT1
inhibitor is shown in gray. (e) Active site is caspase like.
e) with caspase-2/acetyl-LDESD-aldehyde complex (PDB
ng the numbering used in the PDB entry 1pyo. MALT1 and
due are shown as sticks. (f) Ligand binding is caspase like.
-LDESD-aldehyde (caspase-2, yellow).
Fig. 5. MALT1 is an arginine-speciﬁc protease. (a) The P2-to-P4 substrate speciﬁcity of full-length MALT1 (2–824)
expressed from insect cells was mapped in the presence of kosmotrope using positional scanning libraries, by measuring
the release of the chromophore acc from tetra-peptide substrates. P1 was kept ﬁxed as an arginine. Either position P2, P3,
or P4 was scanned (O), while the two remaining positions were randomized (X) with 19 different amino acids, including
the non-natural amino acid norleucine but without the oxidation sensitive amino acids methionine and cysteine. Activities
are normalized relative to the turnover measured for Ac-LXXR-acc. (b) MALT1 cleavage sites in previously described
endogenous substrates. Please note that NIK is cleaved by API2-MALT1 fusion oncoprotein and not MALT1. (c) Evidence
that natural substrates are only cleaved after arginine but not lysine: A20 wild type (with an arginine at position 439) or
the R439K mutant co-expressed with HLH-MALT1 in HEK293 and analyzed by Western blot. A20p50 is the major
MALT1-dependent proteolytic fragment of A20, generated upon cleavage at R439. * and ** refer to A20 fragments
resulting from cleavage at secondary, uncharacterized sites.39 Cleavage at these sites is enhanced when the major cleavage
site (R439) is compromised.
13Determinants of MALT1 Protease Activity(standard orientation as in Fig. 4c) is delineated by
the aliphatic side chain of L359, which is close to the
aliphatic portion of the P1 arginine. The proline in
P2 position is in close proximity to the side chain of
F499, while the arginine in P3 is exposed to solvent;
its side chain barely interacts with the protein and
even adopts different conformations in the
hMALT1Casp and mMALT1Casp-Ig3 structures. Final-
ly, the side chain of valine P4 in MALT1 is
accommodated in a hydrophobic pocket formed
by F499, I510, L541, and T542 (Fig. 4c and f).
The binding mode of the peptidic inhibitor is in
good agreement with the primary substrate spec-
iﬁcity of MALT1. Mapping of subsites S1 to S4
using peptide libraries33,34 identiﬁed Ac-LISR-7-
amino-4-carbamoylmethylcoumarin (acc) as the
optimal tetra-peptidic substrate for full-length
hMALT1 in an in vitro assay in the presence of
kosmotrope (Fig. 5a). Subsequent kinetic analysisshowed that Ac-LISR-amc and the BCL10-based
substrate Ac-LRSR-Rh110-DP were cleaved with
similar efﬁciencies (Table 1). The restricted S2
pocket is too small to accept bulky residues,
explaining the selectivity for serine, alanine, and
proline in P2. The shallow, hydrophobic S4 pocket
is open to accommodate larger hydrophobic resi-
dues, while no hydrogen donors or acceptors are
present to counterbalance a charged P4 residue or
to form speciﬁc hydrogen bonds with polar side
chains. In contrast, no speciﬁc interactions are
observed with the P3 residue, an observation that
is in agreement with the small contribution of this
residue for substrate recognition.
The in vitro speciﬁcity proﬁle is in line with the
cleavage site sequence of endogenous MALT1 sub-
strates. All cellular substrates reported so far possess
an arginine in P1 and a serine in P2 (Fig. 5b).6,7,35–37
Conservation of residues in P3 and P4 is less
14 Determinants of MALT1 Protease Activitystringent. Still, the results from the positional
mapping and our structural analysis are by and
large in agreement with the speciﬁcity proﬁle
gathered from the endogenous substrates, as P3
contributes weakly to the overall substrate selectiv-
ity and P4 accepts a variety of hydrophobic residues.
In addition, the cleavage site sequences of natural
MALT1 substrates provide information on the P1′
(the position that follows the cleavage site) selectiv-
ity. In line with the reported P1′ selectivity of
caspases,38 small residues especially glycine appear
to be preferred. According to the subsite mapping,
human A20 does not represent an optimal substrate
with a glycine at position P4. Indeed, a subsequently
synthesized A20-based substrate spanning P4 to P2′
is cleaved more than 10 times less efﬁcient than the
corresponding BCL10-based substrate (Supplemen-
tary Fig. 7). Positional scanning using peptidic
substrates provides an incomplete picture of the
selectivity of proteases, and A20 in its cellular
environment might be as efﬁciently cleaved as
other proteinaceous substrates, as the substrate–
protease recognition can engage binding sites
outside of the substrate binding cleft. However,
even the most relevant endogenous substrate of a
protease is not necessarily cleaved with highest
possible efﬁciency.
In vitro substratemapping, structural analysis, and
the proﬁle of natural MALT1 substrates suggest that
MALT1 requires an arginine in P1 and does not
accept lysine. To probewhether this translates to full-
length substrates, we mutated the MALT1 cleavage
site of A20 (R439) into a lysine. Indeed, A20 cleavage
by the constitutively active HLH-MALT1 fusion
protein39 in HEK293 cells is abrogated by this
mutation (Fig. 5c), conﬁrming that MALT1 is very
stringent at its P1 position in vitro and in cells.
Comparison of hMALT1Casp/Z-VRPR-fmk to
other caspase inhibitor complexes reveals the
initiator caspase-2, caspase-9, and caspase-8 as the
closest homologues. Superposition of caspase-2
(PDB entry 1pyo) onto hMALT1Casp/Z-VRPR-fmk
results in an rmsd of 1.75 Å for 186 Cα positions,
with slightly worse agreements for caspase-8 and
caspase-9. In all analyzed caspase–peptide com-
plexes, the antiparallel β-sheet between the inhibitor
backbone and loop L3 is present. Indeed, Ac-
LDESD-aldehyde bound to caspase-2 and Z-VRPR-
fmk bound to hMALT1Casp adopt an identical
position (Fig. 4e and f), corroborating that the
binding modes are equivalent. The inversed charge
selectivity in S1 of caspases compared to MALT1
(aspartate instead of arginine in caspases40,41) is not
mirrored by a simple charge reversal of the
corresponding amino acid positions fencing the S1
pocket in caspases (Fig. 4e). This is a consequence of
the longer side chain of the arginine that protrudes
much deeper into the S1 pocket than the correspond-
ing short aspartate in caspases. The respectivesubstrate charges are countered by amino acids in
structurally different positions. In MALT1, the
positive charge of the arginine in P1 is countered
by three negative charges: E500 on the L3 loop, D462
just two residues N-terminal of the catalytic cyste-
ine, and D365 that protrudes from a helical segment
close to L1 to form the bottom of the S1 pocket. The
structurally equivalent residues in caspases, R341,
Q283, and D185 (caspase-1 numbering; see Fig. 3),
are highly conserved. R341 (R231 in Fig. 4e) is the
only one of these three residues with a charge
reversal and strictly conserved in all caspases. Q283
(Q153 in Fig. 4e) is in hydrogen bonding distance to
the carboxyl group of the aspartic acid in S1,
contributing to the selectivity of caspases for
aspartate in P1. A negatively charged residue is
found at the bottom of the S1 pocket of caspases, but
due to the short side chain of aspartic acid, the
carboxylates of the substrate P1 residue and D185
(D60 in Fig. 4e) remain at a distance of 6 Å. All
caspases have with R179 (R54 in Fig. 4e) one
additional positive charge lining the entrance of
the P1 pocket that also contributes to their P3
selectivity for negatively charged side chains; this
residue corresponds to L359 in MALT1 where it
forms hydrophobic interactions with the aliphatic
portion of the P1 arginine. Finally, the S1 pocket in
MALT1 is much deeper compared to caspase-2 or
other caspases, as they all possess a serine (S237 in
Fig. 4e) or threonine in the position of G509 in
MALT1.
Long-range structural changes induced by
ligand binding
Besides restructuring of the active site, ligand
binding induces a number of long-range effects and
even affects the relative orientation of the Ig-like
domain with respect to the caspase domain.
Superimposition of the MALT1 catalytic domain in
its active with the inactive state results in an rmsd of
1.4 Å for 200 for the 234 common Cα positions. Due
to small changes in the MALT1 dimer interface,
including the restructuring of loop L2, the superim-
position of dimeric structures even yields an rmsd of
2.3 Å for 382 out of 468 common Cα positions. This
domain movement is a consequence of a concerted
shift of several helices (Fig. 6a and b). As described
above, binding of the peptidic inhibitor completely
rearranges loop L3: the side chain of Q494 shifts 16 Å
from the S1 pocket toward the dimer interface, and
the carboxylate of E500 moves 12 Å from a solvent-
accessible position in the inactive state to form tight
interactions with the substrate arginine in the active
conformation. This movement locks the catalytic
cysteine C464 in its active position and allows the
neighboring residue R465 to form a salt bridge with
the side chain of E549 (Figs. 4a, 4b, 6c, and 6d). The
entire L2 loop becomes visible in the electron density
15Determinants of MALT1 Protease Activityand is stabilized by a hydrophobic cluster formed
between P475 and I474 on L2 as well as Y417, F420,
and F424 on sheets β3A and β3B (Fig. 6b). Residue
L480 on loop L2 is in direct interactions with L446 on
helix αD, which shifts at its distal end by 7 Å towardFig. 6 (legend ohelix αC and is forced closer toward helix α1Ig3, the
connecting segment between the catalytic and Ig-
like domains (Fig. 6a). In addition to the changes of
Cα positions, numerous side chains of aromatic
residues undergo a concerted movement (Fig. 6cn next page)
Fig. 7. Dimer interface mutants
do not support MALT1-dependent
BCL10 cleavage. (a) Close-up of
MALT1 dimer interface of ligand-
free MALT1 (light blue; symmetry
mate in dark blue). The conforma-
tion of R551 in ligand-free MALT1
is shown in red; that in ligand
bound is shown in green. (b) Pro-
cessing of full-length BCL10 by
MALT1 R551V and MALT1 R551E
upon co-expression with CARD11
L244P in HEK293 cells. For exper-
imental details, see Fig. 1c and
Methods.
16 Determinants of MALT1 Protease Activityand d). As a result, helix α1Ig3 rotates roughly 45°
and elongates by one turn (Fig. 6a). This rearrange-
ment changes the interactions of the helical linker
α1Ig and the catalytic domain, as well as Ig-like
domain, substantially. For example, in ligand-free
MALT1, W580 on helix IIg is part of a hydrophobic
cluster formed by residues located on helix αC
(L401), strand β1 (L346), and β2 (V381) (Fig. 6e and
f). In the ligand-bound structure, the tryptophan
side chain is displaced by 10 Å and moves into a
partially solvent-accessible environment. In addi-
tion, R719, which interacts with the backbone
carbonyl atoms of residues 712 and 715 in the
ligand-free structure, shifts toward E397 upon
ligand binding. Although the 100 C-terminal resi-
dues are not present in the structure, it is likely that
this rearrangement alters the relative orientation of
this domain. The C-terminus together with the third
Ig-like domain is involved in the interaction with
binding partners such as TRAF6. It is conceivable
that binding of TRAF6 impacts on the structure of
the catalytic site or vice versa and thereby regulates
substrate recognition or turnover.
MALT1 interface mutants cannot cleave BCL10
in cells
At the center of the 2-fold symmetry of theMALT1
dimer is R551. Both in the ligand-bound state and in
the ligand-free state, this residue and its symmetryFig. 6. Long-range structural changes induced by ligand bin
in blue and murine MALT1Casp-Ig3/Z-VRPR-fmk in green. For
shown as loops instead of arrows. Residues in the murine M
MALT1 sequence. (a) Global superimposition of MALT1Ca
mMALT1Casp-Ig3 is shown in green. Helices αC, αD, and α
restructure upon ligand binding. The structural elements are s
the ligand-free hMALT1Casp-Ig3 has been omitted. Loop L2 (red
the dimer interface in the same orientation as in (a), but global s
on the right is highlighted in darker colors. In the ligand-boun
hydrophobic cluster formed by residues on loop L2 and on str
site in the same orientation. Please note the restructuring of l
residues in the hydrophobic core of the molecule. (e and f) Clmate are in direct contact through the aliphatic
portion of their side chain. While in the ligand-free
structure, the guanidinium groups are only 3.9 Å
apart: the ideal distance for a π–π stacking; they are
separated by at least 8 Å in the ligand-bound form
(Fig. 7a) and adopt a conﬁrmation that is only
accessible because of the described movement of
helix αD (Fig. 6a). Introduction of a negatively
charged aspartate into caspase-8 and caspase-9 at
the equivalent positions (390 in caspases number-
ing) has been shown to prevent dimerization, and
such mutants were no longer able to induce
apoptosis.18
In analogy, single-point mutations at the dimer
interface impair the ability of MALT1 to cleave
BCL10 in the CBM reconstitution assay (see above).
Besides a radical charge reversal mutation R551E to
generate inactive MALT1, a neutral mutation
R551V, which still supports dimerization, was
introduced into full-length MALT1 (Fig. 7b). Each
mutant was co-transfected with BCL10 and
CARD11 (L244P) into HEK293 cells, and both
BCL10 and MALT1 were detected by Western blot.
MALT1 R551V was able to cleave BCL10. Treatment
of the cells with Z-VRPR-fmk led to a reduction in
BCL10 cleavage, showing that, in this assay, the
dimerization neutral mutation R551V does not
impede MALT1 activity. In contrast, no BCL10
cleavage was observed with MALT1 R551E. These
data show that an intact dimer interface is requiredding: superimposition of humanMALT1Casp-Ig3 ligand free
clarity, the sheets β3A and β3B in (c), (d), (e), and (f) are
ALT1 structure are numbered according to the human
sp monomers. The complete molecule of ligand-bound
1Ig3; sheets β3A and β3B; and loops L2–L4 of MALT1
hown as in the ligand-free structure (blue), and the rest of
) is deﬁned in the ligand-bound form only. (b) Close-up of
uperimposition of theMALT1 dimers. The symmetrymate
d form, the conformation of loop L2 (red) is stabilized by a
ands β3A and β3A. (c and d) Close-up of MALT1 catalytic
oop L2 and the different rotation of several hydrophobic
ose-up of MALT1Casp-Ig3 domain interfaces.
17Determinants of MALT1 Protease Activityfor MALT1 activity and is an indication that CBM-
driven MALT1 activation might lead to a direct
interaction between two MALT1 molecules as seen
in the structures described here.Summary
More than a decade ago, it was predicted that
MALT1, in addition to immunoglobulin-like do-
mains and an N-terminal death domain, also
contains a caspase-like domain.12 Since then, it
could be demonstrated that MALT1 indeed pos-
sesses catalytic activity, but in contrast to caspases,
MALT1 cleaves its endogenous substrates BCL10,
A20, CYLD, and RelB6,7,35,37 not after an aspartic
acid but after arginine.
Here, we show that in vitro processing of peptidic
substrates by MALT1 is dependent on the presence
of kosmotropic salts and that addition of an
irreversible peptidic induces MALT1 dimerization.
These data indicate that MALT1 follows the general
activation theme of initiator caspases that is depen-
dent on dimerzation.15,18,20 The structural work
reveals that the protease domain of MALT1 is
indeed a caspase with the initiator caspase-9 as the
closest relative. In its ligand-free form, MALT1 is a
dimer but adopts an inactive conformation. Loop
L2, which carries the active cysteine, is only partially
visible in the electron density, and the catalytic
machinery is misaligned. Loop L3, which is
involved in substrate recognition, adopts an inactive
conformation and cannot bind substrates. Finally,
the S1 pocket of the protease is occupied by the side
chain of residue Q494. Thus, MALT1 in its unli-
ganded from, although present as a dimer, is in an
auto-inhibited state and unable to accommodate
and process substrates.
This clearly demonstrates that, for MALT1
activation, dimerization is only the ﬁrst step and
has to be followed by structural rearrangements
that could be induced by substrate binding. Indeed,
the ligand-bound structure of MALT1 shows the
protease in the active conformation, with a mature
substrate binding site and aligned catalytic ma-
chinery. Interestingly and unlike in other caspases,
L2 connecting the large and small subunits in
caspases is well deﬁned in the electron density, and
thus, MALT1 represents the ﬁrst example of an
initiator caspase in the active conﬁguration, with-
out being proteolytically processed. Linked to the
rearrangement of the active site, there occur
numerous signiﬁcant structural changes through-
out the molecule, which affect the interaction
between the caspase and the C-terminal Ig-like
domain. Future studies will clarify the role of the
domains N- and C-terminal to the caspases domain
in the activation, recruitment, and processing of
substrates by MALT1.Methods
Protein production
Details on the design of the expression constructs are
provided as Supplementary Material. In all expression
constructs, the MALT1 coding sequences are preceded
by a ZZ-tag,42 a tandem IgG binding domain, a 6-His-
tag, an S-tag, and a human rhinovirus 3C protease
cleavage site (Supplementary Fig. 1). The nomenclature
used to describe the different variants is explained in
Fig. 1a. For example, human full-length MALT1 is called
hMALT1DD-Ig1-Ig2-Casp-Ig3-Cterm (2–824), and the variant
where the ﬁrst three domains (1–328) have been deleted
is called hMALT1Casp-Ig3-Cterm (329–824).
Proteins for enzymatic studieswere exclusively expressed
in Spodoptera frugiperda (SF 21) cells using baculovirus-based
expression systems (pFastBac, Invitrogen; pTriEx, Nova-
gen). This is because full-length MALT1 and most of the
deletion variants were difﬁcult to express in E. coli and
because naive E. coli (BL21) lysates appear to contain an
endogenous protease that cleaves the MALT1 substrate
Ac-LRSR-Rh110-DP (datanot shown). For structural studies,
a number of further truncated constructs were generated
and expressed both in insect cells and in E. coli (pET or
pTriEx vector systems, Novagen) without changing the
general design of the construct. Once the structure of
mMALT1Casp-Ig3 became available, optimized constructs
for crystallization without ﬂexible N- and C-terminal
extensions were designed. One of these constructs, human
MALT1Casp-Ig3 (334–719), was expressed from E. coli and
could be crystallized in the absence of ligand (see below).
Protein expression and puriﬁcation followed standard
protocols. In short, a ﬁrst puriﬁcation on an afﬁnity column
(Ni-column)was followedby ion-exchange chromatography
and aﬁnal polishing step by size-exclusion chromatography.
The ZZ-tag was removed by protease cleavage prior to ion-
exchange chromatography from samples designated for
structural studies. Theﬁnal bufferwas 25mMHepes–NaOH
(pH 7.5), 50 mM NaCl, and 1 mM tris(2-carboxyethyl)
phosphine (TCEP) for all protein preparations.
Protease assay
Protease activity was determined using the ﬂuorogenic
substrate Ac-LRSR-Rh110-DP (Biosyntan), a rhodamine-
based ﬂuorophore in which one amino group is modiﬁed
with D-proline and the other is modiﬁed with the peptide
Ac-LRSR. All the MALT1 samples used in enzymatic
studies were expressed from insect cells, and their enzyme
concentrations were determined by reversed-phase
HPLC. The peak area of the elution peak was recorded
at 216 nm, and concentration was calculated using a
calibration curve (bovine serum albumin standard).
MALT1 samples were diluted in reaction buffer [25 mM
Hepes–NaOH (pH 7.4) or 200 mM Tris–HCl (pH 7.5),
1 mM DTT or TCEP, 0.05% Chaps, and 0.1 mM
ethylenediaminetetraacetic acid (EDTA) or ethylene glycol
bis(β-aminoethyl ether) N,N′-tetraacetic acid (EGTA)].
Protease activity was monitored both in the presence
and in the absence of 0.8 M sodium citrate. Reaction
mixtures were incubated at room temperature over 1 h ,
with MALT1 concentrations between 25 nM and 400 nM
18 Determinants of MALT1 Protease Activityand 1 μM substrate. Fluorescence intensity (excitation,
485 nm; emission, 535 nm) increase was measured in
either an Envision or a Tecan Inﬁnite (Tecan) plate reader
for up to 80 min ; no substrate depletion was observed (see
Supplementary Fig. 4b).
Combinatorial peptide library analysis
The combinatorial libraries used to proﬁle subsite
speciﬁcity of MALT1 contained mixtures of tetra-peptide
substrates in a positional scanning format. In this library,
two positions are always ﬁxed, while the two remaining
positions are randomized with an equimolar mixture of
19 amino acids. Methionine is replaced by the isostere
norleucine (Nle), and cysteine is excluded. The general
use of combinatorial ﬂuorogenic substrates for the
proﬁling of protease speciﬁcity has been described
elsewhere.33 MALT1 was diluted in assay buffer
[25 mM Hepes–NaOH (pH 7.4), 0.1 mM EDTA, 0.05%
Chaps, 1 mM TCEP, and 0.8 M sodium citrate], and
substrate hydrolysis was initiated by dispensing 49 μl of
enzyme in assay buffer into the microplates at a ﬁnal
concentration of 290 nM. Each well contains an equimolar
mixture of 361 peptides (optimal and suboptimal
sequences), with each peptide comprising two ﬁxed
positions and two randomized positions. The ﬁnal
concentration of the tetra-peptide substrate was
0.15 μM each peptide per well in 50 μl reaction buffer.
Protease activity was monitored by measuring the release
of acc from tetra-peptide substrates using a Molecular
Devices Gemini XS instrument (Molecular Devices) with
excitation wavelength at 380 nm and emission wave-
length at 450 nm at room temperature for 3 h . Further
details on the experimental setup used for MALT1 can be
found in Supplementary Material.
Cell culture, transfection, and Western blot analyses
For expression, the cDNA inserts of BCL10, A20, and
CARD11 L244P13 were transferred into pcDNA6.2DEST
or a modiﬁed version of pCMVSport 1 (both Invitrogen).
Details on the HLH-MALT1-expressing construct (LMBP
6102) are available online‡. Site-directed mutagenesis was
performed with the QuikChange Site-Directed Mutagen-
esis Kit (Stratagene). HEK293 cells were grown in 10%
(wt/vol) fetal calf serum containing DMEM (Dulbecco's
Modiﬁed Eagle's Medium) and plated at 1× 105 cells per
well in a 24-well plate (Nunc). After 12 h , cells were
transfected using FuGene HD (Roche) and harvested after
24 h in 200 μl cell lysis buffer (Cell Signaling Technology),
supplemented with 10 mM Pefabloc. Murine anti-FLAG
M2 (Sigma, #F3165), murine anti-BCL10 (Santa Cruz, #sc-
5273), and rabbit anti-BCL10 neo-epitope raised by
Charles River Laboratories against the BCL10-based
peptide FLPLRSR were used. The secondary antibodies
used were either a goat anti-rabbit IgG conjugated to
IRDye800CW (LI-COR Biosciences, #926-32211) or a goat
anti-murine IgG (H+L) F(ab′)2 fragment conjugated to
Alexa Fluor-680 (Molecular Probe, #A21059).‡http://bccm.belspo.be/about/lmbp.htmStructural studies
Different human andmurineMALT1 variants both in the
ligand-free and in the ligand-bound forms (Supplementary
Material) were used in crystallization trials at a concentra-
tion of 10–15mgml−1. To form theMALT1–ligand complex,
we added a 4× molar excess of Z-VRPR-fmk (Bachem) to a
concentrated protein solution (10 mg ml−1). After 2–4 h of
incubation at room temperature modiﬁed, dimeric protein
was separated by size-exclusion chromatography (e.g., see
Supplementary Fig. 5) and concentrated.
mMALT1Casp-Ig3 in complex with Z-VRPR-fmk
The constructs murine MALT1 (338–832) and the
analogous construct human MALT1 (329–824) were
designed based on the domain prediction and expressed
in insect cells. Crystals of mMALT1 (338–832)/Z-VRPR-
fmk complex appeared overnight at 22 °C from 200 mM
lithium sulfate and 100 mM 2-[bis(2-hydroxyethyl)
amino]-2-(hydroxymethyl)propane-1,3-diol propane
(pH 7.0). Subsequent mass spectrometry analysis of
protein from crystallization trials showed that MALT1
had been cleaved after residue 728 (murine sequence).
hMALT1Casp in complex with Z-VRPR-fmk
Human MALT1Casp-Ig3-Cterm (329–824)/Z-VRPR-fmk
was incubated overnight at room temperature with a
1:1000 molar ratio of chymotrypsin/MALT1. A stable
fragment with a mass of 28,334 Da, corresponding to the
caspase domain (329–569), could be isolated and crystal-
lized from 20% polyethylene glycol 3350 (wt/vol),
100 mM ammonium nitrate, and 100 mM 2-[bis(2-
hydroxyethyl) amino]-2-(hydroxymethyl)propane-1,3-
diol propane (pH 7.0) at 22 °C.
hMALT1Casp-Ig3 (334–719) ligand free
The construct was designed based on the structure of
mMALT1Casp-Ig3 in complex with Z-VRPR-fmk. The
dimeric species of human MALT1Casp-Ig3 (334–719),
expressed in E. coli, was isolated by ion-exchange and
size-exclusion chromatography. Well-diffracting crystals
formed at 22 °C within 1–2 days when using 20%
polyethylene glycol 3350 (wt/vol) and 200 mM magne-
sium formate as crystallization buffer.
All crystals were ﬂash cooled in liquid nitrogen after the
addition of 20% (vol/vol) glycerol to the crystallization
solution. Diffraction data were collected at the wavelength
of 1 Å on beamline X10SA (PXII; Swiss Light Source,
Villigen, Switzerland) and processed using XDS43 as part
of the APRV package44 (Table 2). All structures in this
study were solved by Patterson methods using the
program Phaser.45 The structure of hMALT1Casp/Z-
VRPR-fmk was solved using caspase-2 as search model
(PDB entry 1pyo). The molecular model was improved in
Coot46 and reﬁned using Buster§ and Refmac:47 220 (95%)
residues of the ﬁnal model fall in the preferred region of
the Ramachandran plot, 10 (4.5%) residues of the ﬁnal
model fall in the allowed region, and 1 (0.5%) residue is an
outlier. The structure of mMALT1Casp-Ig3/Z-VRPR-fmk§http://www.globalphasing.com/
19Determinants of MALT1 Protease Activitywas solved at 3.15 Å using hMALT1Casp/Z-VRPR-fmk as
a search model. Despite the low resolution of the available
data set, an additional 153 residues (577–729) could
rapidly be placed in the electron density: 356 (92%)
residues of the ﬁnal model fall in the preferred region of
the Ramachandran plot, 19 (5%) residues of the ﬁnal
model fall in the allowed region, and 11 (3%) residues are
outliers. Finally, the model of mMALT1Casp-Ig3/Z-VRPR-
fmk served as search molecule to solve the structure of
ligand-free hMALT1Casp-Ig3 (334–719) at a resolution of
1.92 Å: 331 (95%) residues of the ﬁnal model fall in the
preferred region of the Ramachandran plot, 11 (3.1%)
residues of the ﬁnal model fall in the allowed region, and 6
(2%) residues are outliers. For details on the quality of the
ﬁnal model, please refer to Table 2. All structure ﬁgures in
this manuscript have been generated with PyMOL∥.
Accession codes
The structures described within this manuscript have
been submitted to the PDB: hMALT1Casp-Ig3 ligand free,
3V55 (RCSB069607); hMALT1Casp in complex with
Z-VRPR-fmk, 3V4O (RCSB069590); and mMALT1Casp-Ig3
in complex with Z-VRPR-fmk, 3V4L (RCSB069587).Acknowledgements
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